Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate Kit
Product Images NDC 0378-7303

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate (NDC 0378-7303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (Image 01)

Structural Formula (Image 01)
Chemical structure diagram displaying the molecular structures of norethindrone acetate and ethinyl estradiol, the active ingredients in NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE by Mylan Pharmaceuticals Inc.*
FDA Label Image

Concentrations (Image 02)

Concentrations (Image 02)
Two line graphs depict mean plasma concentrations over 24 hours. The top graph shows mean plasma ethinyl estradiol concentration (pg/mL) with data points for ratios 1/20, 1/30, and 1/35. The bottom graph shows mean plasma norethindrone concentration (ng/mL) with the same ratios over time (hours).*
FDA Label Image

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)
A line graph depicting mean percent reduction in total lesion counts over six treatment cycles comparing Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Tablets versus placebo in an intent-to-treat population. The graph shows higher reduction percentages for the active drug group across cycles, with patient numbers listed below for each cycle.*
FDA Label Image

Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)

Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)
A mortality rate bar chart displaying number of deaths per 100,000 woman users across four age groups (15-24, 25-34, 35-44, 45). Mortality rates are compared among four categories: ever-users non-smokers, ever-users smokers, controls non-smokers, and controls smokers, each with distinct shading patterns.*
FDA Label Image

Blister (Image 05)

Blister (Image 05)
This image shows the patient instruction panel for the NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE kit by Mylan Pharmaceuticals Inc. It includes directions on how to start the medication with a weekly pill layout labeled Sunday through Saturday across four weeks, indicating to take pills from left to right. The panel notes the presence of 28 tablets and specifies active ingredients and their doses along with ferrous fumarate tablets. It includes an Rx only designation and guidance for Day-1 and Sunday starters.*
FDA Label Image

Blister (Image 06)

Blister (Image 06)
This image shows a dosing instruction panel for a kit containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate tablets. It includes a weekly pill schedule organized by days of the week (Sunday to Saturday) over four weeks with arrows indicating the sequence to take 28 tablets from left to right. Additional instructions direct "Sunday starters" and "Day-1 starters" on how to begin usage, and the label notes the specific dosages of each active ingredient per tablet, along with a statement about ferrous fumarate tablets' assay status.*
FDA Label Image

3s Carton (Image 07)

3s Carton (Image 07)
Box packaging label for NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE tablets kit by Mylan Pharmaceuticals Inc. The label shows three tablet strengths: 1 mg norethindrone acetate with 20 mcg, 30 mcg, or 35 mcg ethinyl estradiol, plus 75 mg ferrous fumarate. It indicates a 28-day regimen with 3 pouches containing 28 tablets total.*
FDA Label Image

Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)

Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)
A forest plot chart showing effect estimates (odds ratios/relative risks) with confidence intervals from eight different studies related to contraceptive use, including NICHD Women's Contraceptive Study, French E3N cohort, Shanghai Women's Health Study, The Nurses' Health Study II, Oxford Family Planning Association Study, and Danish Sex Hormone Register Study, comparing ever use and current use metrics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.